|Day Low/High||90.08 / 91.08|
|52 Wk Low/High||82.50 / 184.77|
Deutsche Bank lowered its price target to $105 on Perrigo (PRGO) stock this morning.
U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.
Ralph Lauren shares surge on earnings beat amid lethargic market action.
Perrigo (PRGO) posted weak earnings for the 2016 second quarter and cut its full-year forecast, which Jim Cramer found 'disturbing.'
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
The stock's tumbling to near a 52-week low, but charts suggest caution.
Perrigo (PRGO) reported earnings for the 2016 second quarter, falling short of estimates and cutting guidance for the year.
Perrigo (PRGO) is expected to report second-quarter earnings and revenue that fell from a year ago before tomorrow's market open.
Much to the relief of Bill Ackman and other investors, the Joe Papa-led company also reaffirmed its 2016 guidance on Tuesday.
The stock is up on earnings but there could be violations in agreements with creditors.
Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.
Cramer says he'll be watching Allergan, Tyson and Macy's earnings, among many others. Also, he explains why having money in the stock market is the best path to long-term rewards.
Here are Friday's top research calls, including downgrades for AthenaHealth, Pandora and PayPal, and an upgrade for PulteGroup.
Owning these stocks could be toxic to your portfolio.
Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals
Law Offices of Howard G. Smith reminds investors of the upcoming July 18, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased...
Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.
Endo Pharmaceuticals is most under pressure, analysts say.